Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00754819

Targeting Inflammation in Acute Coronary Syndrome Using Colchicine (COOL)

Colchicine Compared With Placebo to Reduce Hs-CRP in Patients With Acute Coronary Syndromes- Targeting Inflammation in Atherosclerosis Trial

Sponsor: Hamilton Health Sciences Corporation

Conditions Acute Coronary Syndrome

Interventions Colchicine Placebo

Updated 5 times since 2017 Last updated: Oct 7, 2009 Started: Apr 30, 2008 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Acute Coronary Syndrome, this trial is completed. The trial is conducted by Hamilton Health Sciences Corporation and has accumulated 5 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamilton Health Sciences Corporation

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada